HR+ BREAST CANCER

Clinical trials for HR+ BREAST CANCER explained in plain language.

Never miss a new study

Get alerted when new HR+ BREAST CANCER trials appear

Sign up with your email to follow new studies for HR+ BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1 Not yet recruiting 3 Terminated 1

New pill shows promise in early trial for Hard-to-Treat cancers

Disease control Recruiting now

This early-stage study tests a new oral drug, NKT5097, in 205 adults with advanced solid tumors that have not responded to other treatments. The main goals are to find the safest dose and understand side effects. The study focuses on breast cancer and other tumors with specific g…

Matched conditions: HR+ BREAST CANCER

Phase: PHASE1 • Sponsor: NiKang Therapeutics, Inc. • Aim: Disease control

Last updated May 12, 2026 13:39 UTC

HR+ BREAST CANCER

Get alerted when new HR+ BREAST CANCER trials appear

New pill shows promise in early trial for Hard-to-Treat cancers